Orthofix Medical (OFIX) Issues Earnings Results

Orthofix Medical (NASDAQ:OFIX) posted its quarterly earnings data on Monday. The medical device company reported $0.43 EPS for the quarter, beating the Zacks’ consensus estimate of $0.34 by $0.09, MarketWatch Earnings reports. Orthofix Medical had a net margin of 2.53% and a return on equity of 10.74%. The firm had revenue of $111.70 million for the quarter, compared to the consensus estimate of $110.65 million. During the same period in the prior year, the firm posted $0.42 EPS. The firm’s revenue was up 6.2% compared to the same quarter last year. Orthofix Medical updated its FY 2018 guidance to $1.70-1.75 EPS and its FY18 guidance to $1.70-1.75 EPS.

OFIX stock opened at $60.64 on Wednesday. Orthofix Medical has a fifty-two week low of $50.27 and a fifty-two week high of $63.57. The stock has a market capitalization of $1.06 billion, a P/E ratio of 37.43, a PEG ratio of 3.46 and a beta of 0.36.

In other Orthofix Medical news, CEO Brad Mason sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $53.02, for a total transaction of $132,550.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Rice Doug sold 3,949 shares of the firm’s stock in a transaction dated Thursday, October 11th. The shares were sold at an average price of $55.65, for a total transaction of $219,761.85. Following the transaction, the chief financial officer now directly owns 32,368 shares in the company, valued at approximately $1,801,279.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,949 shares of company stock worth $485,487. Corporate insiders own 5.60% of the company’s stock.



A number of research analysts have commented on OFIX shares. Zacks Investment Research upgraded shares of Orthofix Medical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 4th. BidaskClub downgraded shares of Orthofix Medical from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. TheStreet upgraded shares of Orthofix Medical from a “c+” rating to a “b-” rating in a research note on Monday, September 10th. Finally, Cantor Fitzgerald increased their target price on shares of Orthofix Medical to $66.00 and gave the stock an “overweight” rating in a report on Tuesday, August 7th. One analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. Orthofix Medical has an average rating of “Buy” and an average target price of $64.33.

Orthofix Medical Company Profile

Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures.

See Also: Hedge Funds Explained

Earnings History for Orthofix Medical (NASDAQ:OFIX)

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply